Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2011 Dec;33(12):B16-39.
doi: 10.1016/j.clinthera.2011.11.016.

Quantifying clinical relevance in the treatment of schizophrenia

Affiliations
Review

Quantifying clinical relevance in the treatment of schizophrenia

Christoph U Correll et al. Clin Ther. 2011 Dec.

Abstract

Background: To optimize the management of patients with schizophrenia, quantification of treatment effects is crucial. While in research studies, the use of quantitative assessments is ubiquitous, this is not the case in routine clinical practice, creating an important translational practice gap.

Objective: The aim of this study was to examine the relevance, methodology, reporting, and application of measurement-based approaches in the management of schizophrenia.

Methods: We summarized methodological aspects in the assessment of therapeutic and adverse antipsychotic effects in schizophrenia, including definitions and methods of measurement-based assessments and factors that can interfere with the valid quantification of treatment effects. Finally, we proposed pragmatic and clinically meaningful ways to measure and report treatment outcomes.

Results: Although rating scales are ubiquitous in schizophrenia research and provide the evidence base for treatment guidelines, time constraints and lack of familiarity with and/or training in validated assessment tools limit their routine clinical use. Simple but valid assessment instruments need to be developed and implemented to bridge this research-practice gap. In addition, results from research trials need to be communicated in clinically meaningful ways, including the reporting of effect sizes, numbers-needed-to-treat and -harm, confidence intervals, and absolute risk differences. Some important outcomes, such as treatment response, should be reported in escalating intervals using incrementally more stringent psychopathology improvements. Even with quantification, it remains challenging to weigh individual efficacy and adverse effect outcomes against one another and decide on the targeted or desired improvement or outcomes while also incorporating these in patient-centered and shared decision methods.

Conclusions: Quantification of treatment effects in schizophrenia is relevant for patient management, research, and the evaluation of health care systems. Beyond consensus about meaningful outcomes definitions, reporting strategies, pragmatic tool development and implementation, the discovery of novel treatment mechanisms and related biomarkers is hoped to advance measurement-based approaches in schizophrenia and thereby improve patient outcomes.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Treatment Goals and Challenges [10] Adapted from: Kane JM and Correll CU. Dialogues Clin Neurosci. 2010;12(3):345-57 [10]

Similar articles

Cited by

References

    1. Kane JM, Correll CU. Past and present progress in the pharmacologic treatment of schizophrenia. Journal of Clinical Psychiatry. 2010;71(9):1115–24. - PMC - PubMed
    1. Lehman AF, Lieberman JA, Dixon LB, McGlashan TH, Miller AL, Perkins DO, Kreyenbuhl J, McIntyre JS, Charles SC, Altshuler K, Cook I, Cross CD, Mellman L, Moench LA, Norquist G, Twemlow SW, Woods S, Yager J, Gray SH, Askland K, Pandya R, Prasad K, Johnston R, Nininger J, Peele R, Anzia DJ, Benson RS, Lurie L, Walker RD, Kunkle R, Simpson A, Fochtmann LJ, Hart C, Regier D. Practice guideline for the treatment of patients with schizophrenia, second edition. Am J Psychiatry. 2004;161(2):1–56. - PubMed
    1. National Institute for Clinical Excellence. Schizophrenia: Full national guideline on core interventions in primary and secondary care. Royal College of Psychiatrists. 2003
    1. Falkai P, Wobrock T, Lieberman J, Glenthoj B, Gattaz WF, Moller HJ. World Federation of Societies of Biological Psychiatry (WFSBP) - Guidelines for biological treatment of schizophrenia, part 1: Acute treatment of schizophrenia. World J BiolPsychiatry. 2005;6(3):132–191. - PubMed
    1. McGorry PD. Royal Australian and New Zealand College of Psychiatrists clinical practice guidelines for the treatment of schizophrenia and related disorders. Aust N Z J Psychiatry. 2005;39(1-2):1–30. - PubMed

Publication types

Substances